NCT00680485终止1 期
A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 96
- 试验地点
- 2
- 主要终点
- Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests
研究概览
简要总结
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.
详细描述
A three part study in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of repeat escalating oral doses of GSK580416; the safety, tolerability, and pharmacokinetics of GSK580416 following a loading dose regimen; and the effect of ketoconazole on the pharmacokinetics of GSK580416
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults (as determined by medical evaluation including history, physical exam, vital signs, laboratory tests, and cardiac monitoring)
- •Aged 18-60yrs, with BMI of 19-31kg/m
- •Females must be of non-childbearing potential.
- •QTc < 450 msec at screening.
- •Subjects must be able to give consent and comply with restrictions of study.
排除标准
- •Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI condition or history that may place the subject at an unacceptable risk or may interfere with absorption, distribution, metabolism, or excretion of drug.
- •Positive urine drug screen.
- •Positive urine test for alcohol.
- •Positive HIV or Hep B and/or C assay.
- •History of regular tobacco use within 3 monts prior to screening or cotinine levels indicative of smoking at screening.
- •History of regular alcohol consumption (14 units/week for women and 21 units/week for men).
- •History of drug abuse or dependence within 12 months of study.
- •Participation in another drug trial within 30 days of first dose.
- •Exposure to more than 4 new chemical entities within 12 months of first dose.
- •Use of prescription and non-prescription drugs including vitamins, dietary supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of the first dose.
- •Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14 days of first dose.
- •Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is allowed 30 days prior to study participation.
- •A positive immunochemical fecal occult blood test at screening.
- •History of sensitivity to any of the study medications.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •History of orthostatic hypotension or orthostatic hypotension at screening.
结局指标
主要结局
Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests
次要结局
- Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 DaysHealthyNCT00791388Procter and Gamble45
已完成
1 期
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsSchizophreniaNCT00505973Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsSchizophreniaNCT00458107Wyeth is now a wholly owned subsidiary of Pfizer64
已完成
1 期
Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male SubjectsDiabetes MellitusNCT00448032Wyeth is now a wholly owned subsidiary of Pfizer